The role of interferon‐β in the treatment of multiple sclerosis and experimental autoimmune encephalomyelitis – in the perspective of inflammasomes
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Summary: Inflammasomes in innate immune cells mediate the induction of inflammation by sensing microbes and pathogen‐associated/damage‐associated molecular patterns. Inflammasomes are also known to be involved in the development of some human and animal autoimmune diseases. The Nod‐like receptor family pyrin domain containing 3 (NLRP 3) inflammasome is currently the most fully characterized inflammasome, although a limited number of studies have demonstrated its role in demyelinating autoimmune diseases in the central nervous system of humans and animals. Currently, the development of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), is known to be induced by the NLRP 3 inflammasome through enhanced recruitment of inflammatory immune cells in the central nervous system. On the other hand, interferon‐β (IFN β), a first‐line drug to treat MS, inhibits NLRP 3 inflammasome activation, and ameliorates EAE. The NLRP 3 inflammasome is indeed a factor capable of inducing EAE, but it is dispensable when EAE is induced by aggressive disease induction regimens. In such NLRP 3 inflammasome‐independent EAE, IFN‐β treatment is generally not effective. This might therefore be one mechanism that leads to occasional failures of IFN‐β treatment in EAE, and possibly, in MS as well. In the current review, we discuss inflammasomes and autoimmunity; in particular, the impact of the NLRP 3 inflammasome on MS/EAE, and on IFN‐β therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cryopyrin activates the inflammasome in response to toxins and ATP
Mariathasan, S., Weiss, D. S., Newton, K., McBride, J., O'Rourke, K., Roose-Girma, M., Lee, W. P., Weinrauch, Y., Monack, D. M., & Dixit, V. M. (2006) · Nature · doi:10.1038/nature04515 · Cited by 3,080
Hornung, V., Bauernfeind, F., Halle, A., Samstad, E. O., Kono, H., Rock, K. L., Fitzgerald, K. A., & Latz, E. (2008) · Nature Immunology · doi:10.1038/ni.1631 · Cited by 3,065
Innate Immune Activation Through Nalp3 Inflammasome Sensing of Asbestos and Silica
Dostert, C., Pétrilli, V., Van Bruggen, R., Steele, C., Mossman, B. T., & Tschopp, J. (2008) · Science · doi:10.1126/science.1156995 · Cited by 2,658
Non-canonical inflammasome activation targets caspase-11
Kayagaki, N., Warming, S., Lamkanfi, M., Walle, L. V., Louie, S., Dong, J., Newton, K., Qu, Y., Liu, J., Heldens, S., et al. (2011) · Nature · doi:10.1038/nature10558 · Cited by 2,530
The NALP3 inflammasome is involved in the innate immune response to amyloid-β
Halle, A., Hornung, V., Petzold, G. C., Stewart, C. R., Monks, B. G., Reinheckel, T., Fitzgerald, K. A., Latz, E., Moore, K. J., & Golenbock, D. T. (2008) · Nature Immunology · doi:10.1038/ni.1636 · Cited by 2,441
Agostini, L., Martinon, F., Burns, K., McDermott, M. F., Hawkins, P. N., & Tschopp, J. (2004) · Immunity · doi:10.1016/s1074-7613(04)00046-9 · Cited by 1,768
Sutton, C. E., Lalor, S. J., Sweeney, C. M., Brereton, C. F., Lavelle, E. C., & Mills, K. H. G. (2009) · Immunity · doi:10.1016/j.immuni.2009.08.001 · Cited by 1,553
Allen, I. C., Scull, M. A., Moore, C. B., Holl, E. K., McElvania-TeKippe, E., Taxman, D. J., Guthrie, E. H., Pickles, R. J., & Ting, J. P.-Y. (2009) · Immunity · doi:10.1016/j.immuni.2009.02.005 · Cited by 1,113
The Hedgehog Pathway Promotes Blood-Brain Barrier Integrity and CNS Immune Quiescence
Alvarez, J. I., Dodelet-Devillers, A., Kebir, H., Ifergan, I., Fabre, P. J., Terouz, S., Sabbagh, M., Wosik, K., Bourbonnière, L., Bernard, M., et al. (2011) · Science · doi:10.1126/science.1206936 · Cited by 845
The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease
Chabas, D., Baranzini, S. E., Mitchell, D., Bernard, C. C. A., Rittling, S. R., Denhardt, D. T., Sobel, R. A., Lock, C., Karpuj, M., Pedotti, R., et al. (2001) · Science · doi:10.1126/science.1062960 · Cited by 829
Cited by
NLRP3 inflammasome and its inhibitors: a review
Shao, B.-Z., Xu, Z.-Q., Han, B.-Z., Su, D.-F., & Liu, C. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00262 · Cited by 836
“In the absence of immune activators, an internal interaction occurs between the NACHT domain and leucine-rich repeats (LRRs), suppressing the interaction between NLRP3 and ASC, thus preventing assembly of the inflammasome (Inoue and Shinohara, 2013a).”
BackgroundInfluentialThe gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology
Rutsch, A., Kantsjö, J. B., & Ronchi, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.604179 · Cited by 821
Impact of microbiota on central nervous system and neurological diseases: the gut-brain axis
Ma, Q., Xing, C., Long, W., Wang, H. Y., Liu, Q., & Wang, R.-F. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1434-3 · Cited by 748
Pharmacological Inhibitors of the NLRP3 Inflammasome
Zahid, A., Li, B., Kombe, A. J. K., Jin, T., & Tao, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02538 · Cited by 671
Active MLKL triggers the NLRP3 inflammasome in a cell-intrinsic manner
Conos, S. A., Chen, K. W., De Nardo, D., Hara, H., Whitehead, L., Núñez, G., Masters, S. L., Murphy, J. M., Schroder, K., Vaux, D. L., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1613305114 · Cited by 485
25-Hydroxycholesterol suppresses interleukin-1–driven inflammation downstream of type I interferon
Reboldi, A., Dang, E. V., McDonald, J. G., Liang, G., Russell, D. W., & Cyster, J. G. (2014) · Science · doi:10.1126/science.1254790 · Cited by 444
25-Hydroxycholesterols in innate and adaptive immunity
Cyster, J. G., Dang, E. V., Reboldi, A., & Yi, T. (2014) · Nature Reviews Immunology · doi:10.1038/nri3755 · Cited by 388
Principles of inflammasome priming and inhibition: implications for psychiatric disorders
Herman, F. J., & Pasinetti, G. M. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.06.010 · Cited by 115
Role of inflammasomes in multiple sclerosis and their potential as therapeutic targets
Govindarajan, V., de Rivero Vaccari, J. P., & Keane, R. W. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01944-9 · Cited by 110
Structural basis for the oligomerization-facilitated NLRP3 activation
Yu, X., Matico, R. E., Miller, R., Chauhan, D., Van Schoubroeck, B., Grauwen, K., Suarez, J., Pietrak, B., Haloi, N., Yin, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45396-8 · Cited by 78
Cholesterol metabolism: from lipidomics to immunology
Griffiths, W. J., & Wang, Y. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100165 · Cited by 68
“4) (27, 33, 50) raises the question: are the known suppressive effects of type I IFNs on the immune system (80, 81) mediated by 25-HC and its regulation of sterols? Type I IFNs are known to downregulate inflammasome activity and IL-1β production (82), IL-1β being a cytokine produced by activated macrophages as a propr…”
BackgroundKawana, N., Yamamoto, Y., Ishida, T., Saito, Y., Konno, H., Arima, K., & Satoh, J. (2013) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12068 · Cited by 34
Metadata
- Authors
- Inoue, M., & Shinohara, M. L.
- Venue
- Immunology
- Publisher
- Wiley
- Published
- 2013-04-08
- Volume
- 139
- Issue
- 1
- Pages
- 11-18
- ISSN
- 0019-2805 (ISSN-L)
- 1365-2567
- OpenAlex
- W2063758367
- Cited by
- 92
- References
- 15
- FWCI
- 3.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.